Prevention of acute renal failure by anti-endothelin converting enzyme.
抗内皮素转换酶预防急性肾衰竭。
基本信息
- 批准号:09470238
- 负责人:
- 金额:$ 8.26万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:1997
- 资助国家:日本
- 起止时间:1997 至 1998
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Endothelin-1 is thought to play a significant role in acute renal failure induced by cyclosporin A.Endothelin converting enzyme-1 (ECE-1) is a key enzyme to produce endothelin. To investigate the role of ECE-1 in the glomerular and tubular dysfunction induced by cyclosporin A, the effects of cyclosporin A on mENA and protein expression of ECE-1, prepro-ET-1, and ETA and ETB type receptor were studied. Prepro-ET-1 rapidly increased in glomeruli 30 to 60 mm. This rapid increase was followed byan increase in plasma ET-1 levels. These increases were followed by decreased expression of ECE- 1, ETA and ETB type receptor mRNA It is suggested that downregulation of glomerular and tubular ECE-1 expression may be one of defense mechanisms of ET system in acute renal failure induced by cyclosporin A.This downregulation may be caused by increased ET-1 or cyclosporin A itself. To investigate the precise mechanism of downregulation of ECE-1 mRNA, the effects of ET-1 was studied in cultured endothelial cells. Incubation of ETA for 6 hours caused a significant decrease in ECE-1 mRNA expression. This effect was was abolished by co-incubation with BQ788, a specific ETB receptor antagonist , but not by co-incubation with BQ123, a specific ETA receptor antagonist. These results suggested that ET-1 suppressed ECE-1 expression through ETB receptor, indicating the existence of a feedback mechanism of FT-1 on ECE-1 in endothelial cells.
Endothelin-1被认为在环孢素A诱导的急性肾功能衰竭中发挥着重要作用。内皮素转换酶-1(ECE-1)是产生内皮素的关键酶。为了探讨ECE-1在环孢菌素A诱导的肾小球和肾小管功能障碍中的作用,研究了环孢菌素A对mENA以及ECE-1、prepro-ET-1、ETA和ETB型受体蛋白表达的影响。 Prepro-ET-1 在肾小球 30 至 60 mm 中迅速增加。这种快速增加之后血浆 ET-1 水平也随之增加。 ECE-1、ETA、ETB型受体mRNA表达量增加后,肾小球和肾小管ECE-1表达下调可能是环孢素A诱导的急性肾功能衰竭ET系统的防御机制之一。这种下调可能是由ET-1或环孢素A本身增加引起的。为了研究 ECE-1 mRNA 下调的精确机制,在培养的内皮细胞中研究了 ET-1 的作用。 ETA 孵育 6 小时导致 ECE-1 mRNA 表达显着降低。与特异性 ETB 受体拮抗剂 BQ788 共孵育可消除该效应,但与特异性 ETA 受体拮抗剂 BQ123 共孵育则不会消除该效应。这些结果表明,ET-1通过ETB受体抑制ECE-1的表达,表明内皮细胞中FT-1对ECE-1的反馈机制的存在。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nakayama Yushi,: "Endothelin-1 inhibits endothelin converting enzyme-1 expression in cultured rat pulmonary endothelial cells." Circulation. 97. 234-236 (1998)
Nakayama Yushi,:“内皮素-1 抑制培养的大鼠肺内皮细胞中内皮素转换酶-1 的表达。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Naomi, S., T.Iwaoka, T.Disashi, J.Inoue, Y.Kanesaka, H.Tokunaga, K.Tomita.: "Endothelin -1 inhibits endothelin converting enzyme-1 expression in cultured rat pulmonary endothelial cells." Circulation. 97. 234-236 (1998)
Naomi, S.、T.Iwaoka、T.Disashi、J.Inoue、Y.Kanesaka、H.Tokunaga、K.Tomita.:“内皮素 -1 抑制培养的大鼠肺内皮细胞中内皮素转换酶 1 的表达。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Y. Kitamoto,: "Vascular endothelial growth factor (VEGF) is an essential molecule for mouse kidney development : glomerulogenesis and nephrogenesis." J. Clin. Invest.,. 99. 2351-2357 (1997)
Y. Kitamoto:“血管内皮生长因子 (VEGF) 是小鼠肾脏发育的重要分子:肾小球发生和肾发生。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kitamoto Y.: "Vascular endothelial growth factor(VEGF)is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis." J.Clin.Invest.99. 2351-2357 (1997)
Kitamoto Y.:“血管内皮生长因子(VEGF)是小鼠肾脏发育的重要分子:肾小球发生和肾发生。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nakayama Yushi,: "Intranephron distribution and regulation of endothelin converting enzyme - 1 in cycloporine A - induced acute renal failure in rats." J.Am.Soc.Nephrol.(in press). (1998)
Nakayama Yushi,“环孔素 A 中内皮素转换酶 - 1 的肾内分布和调节 - 诱导大鼠急性肾衰竭。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TOMITA Kimio其他文献
TOMITA Kimio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TOMITA Kimio', 18)}}的其他基金
Mechanism of prostasin-induced aldosterone production
前列腺素诱导醛固酮产生的机制
- 批准号:
20390238 - 财政年份:2008
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of drug by use of protease cascade of prostasin
利用前列腺素的蛋白酶级联开发药物
- 批准号:
18390252 - 财政年份:2006
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Antibody treatment against hypertension
抗高血压抗体治疗
- 批准号:
16390246 - 财政年份:2004
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis of the function of prostasin in the transgenic mice.
转基因小鼠前列腺素的功能分析。
- 批准号:
14370321 - 财政年份:2002
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Role of renal arginase in acute renal failure
肾精氨酸酶在急性肾衰竭中的作用
- 批准号:
11470219 - 财政年份:1999
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Role of endothelin converting enzyme in essential hypertension
内皮素转换酶在原发性高血压中的作用
- 批准号:
09557091 - 财政年份:1997
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular biological analysis of the mechanism of acute renal failure
急性肾衰竭机制的分子生物学分析
- 批准号:
07457242 - 财政年份:1995
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidation of the mechanism of essential hypertension making a transgenic mice made by putative kallikrein binding protein
阐明原发性高血压的机制,用假定的激肽释放酶结合蛋白制备转基因小鼠
- 批准号:
05557054 - 财政年份:1993
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
Elucidation of mechanism of acute renal failure by use molecular biological techniques
利用分子生物学技术阐明急性肾衰竭的机制
- 批准号:
04454234 - 财政年份:1992
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
Research of the mechanism and treatment for acute renal failure-role of endothelin-
急性肾功能衰竭的机制及治疗研究-内皮素的作用-
- 批准号:
02670273 - 财政年份:1990
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Second generation arylhydrocarbon receptor antagonist, utrophin modulators for the treatment of Duchenne muscular dystrophy
第二代芳基烃受体拮抗剂、肌营养不良蛋白调节剂,用于治疗杜氏肌营养不良症
- 批准号:
MR/X014118/1 - 财政年份:2023
- 资助金额:
$ 8.26万 - 项目类别:
Research Grant
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 8.26万 - 项目类别:
Methocinnamox (MCAM): A novel opioid receptor antagonist
Methocinnamox (MCAM):一种新型阿片受体拮抗剂
- 批准号:
10844948 - 财政年份:2023
- 资助金额:
$ 8.26万 - 项目类别:
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)
选择性糖皮质激素受体拮抗剂治疗患有创伤后应激障碍 (PTSD) 退伍军人的 IIa 期试验
- 批准号:
10596461 - 财政年份:2022
- 资助金额:
$ 8.26万 - 项目类别:
Phase I/IIa Clinical Trial Using Localized and Systemic Delivery of the P2X7 Receptor Antagonist AZD9056 for the Treatment of Salivary Gland Dysfunction in Sjögren's Syndrome Patients
使用 P2X7 受体拮抗剂 AZD9056 局部和全身给药治疗干燥综合征患者唾液腺功能障碍的 I/IIa 期临床试验
- 批准号:
10487866 - 财政年份:2022
- 资助金额:
$ 8.26万 - 项目类别:
Development of a novel anti-gastric cancer drug targeting the Hippo pathway with a thrombin receptor antagonist
使用凝血酶受体拮抗剂开发针对 Hippo 通路的新型抗胃癌药物
- 批准号:
22K07260 - 财政年份:2022
- 资助金额:
$ 8.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical investigation of topical delivery of a muscarinic receptor antagonist for the prevention of chemotherapy-induced peripheral neuropathy
局部给药毒蕈碱受体拮抗剂预防化疗引起的周围神经病变的临床研究
- 批准号:
10324216 - 财政年份:2021
- 资助金额:
$ 8.26万 - 项目类别:
A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.
一种新型高选择性食欲素 1 受体拮抗剂,用于治疗阿片类药物使用障碍患者。
- 批准号:
10322644 - 财政年份:2021
- 资助金额:
$ 8.26万 - 项目类别:
CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse
CVL-354,一种 kappa 阿片受体拮抗剂,用于治疗阿片类药物使用障碍、戒断和复发
- 批准号:
10321502 - 财政年份:2021
- 资助金额:
$ 8.26万 - 项目类别:
Investigating the neuroprotective potential of interleukin-1 receptor antagonist (IL-1Ra) after soman exposure
研究梭曼暴露后白细胞介素 1 受体拮抗剂 (IL-1Ra) 的神经保护潜力
- 批准号:
NE/V019848/1 - 财政年份:2021
- 资助金额:
$ 8.26万 - 项目类别:
Research Grant














{{item.name}}会员




